Risk Factors for Mortality in Candida auris Bloodstream Infection: A Multicenter Study in South Korea, 2018–2025
Authors:
Open Access
- 15 July 2026
- journal article
- research article
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (7) , 519
Abstract
Candida auris (C. auris) is a multidrug-resistant pathogen that spreads clonally in healthcare settings and was designated an urgent threat by the Centers for Disease Control and Prevention in 2019. We conducted a multicenter study to identify mortality risk factors in C. auris bloodstream infection (BSI) in South Korea. In this retrospective cohort study across three tertiary centers, 50 adults with first-episode C. auris BSI were analyzed. Primary and secondary outcomes were 30- and 90-day mortality. 30-day mortality was 24%, and 90-day mortality was 46%. Older age and higher Sequential Organ Failure Assessment score were independently associated with 30-day mortality. Microbiologic clearance within 30 days was protective. For 90-day mortality, older age was the only independent risk factor, and microbiologic clearance within 90 days was also protective. In conclusion, C. auris BSI causes substantial 30-day mortality, underscoring the need for risk-stratified, clearance-focused management.Keywords
This publication has 26 references indexed in Scilit:
- Analysis of Candida auris resistance and associated risk factors in hospitalized patients at a tertiary care hospital in ChinaScientific Reports, 2025
- Comparison of risk factors and mortality of candidemia by Candida auris versus Candida non -auris in intensive care unitsInfectious Diseases, 2025
- How to interpret MICs of amphotericin B, echinocandins and flucytosine against Candida auris (Candidozyma auris) according to the newly established European Committee for Antimicrobial Susceptibility Testing (EUCAST) breakpointsClinical Microbiology and Infection, 2025
- Diagnostic and clinical management of Candida auris infections in immunocompromised patientsExpert Review of Anti-infective Therapy, 2025
- Factors Associated With Poor Clinical and Microbiologic Outcomes in Candida auris Bloodstream Infection: A Multicenter Retrospective Cohort StudyClinical Infectious Diseases, 2024
- Comparative Outcomes of Candida auris Bloodstream Infections: A Multicenter Retrospective Case-Control StudyClinical Infectious Diseases, 2022
- Comparison of in vivo pathogenicity of four Candida auris clades in a neutropenic bloodstream infection murine modelEmerging Microbes & Infections, 2020
- Global epidemiology of emerging Candida aurisCurrent Opinion in Microbiology, 2019
- Multidrug-resistant Candida auris : ‘new kid on the block’ in hospital-associated infections?Journal of Hospital Infection, 2016
- Simultaneous Emergence of Multidrug-ResistantCandida aurison 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological AnalysesClinical Infectious Diseases, 2016